Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $14 from $17 and keeps a Buy rating on the shares.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Earns Buy Rating as Strong Profitability and Balance Sheet Offset Lower 2026 Revenue Outlook
- OptimizeRx reports Q1 EPS 14c, consensus 0c
- OptimizeRx cuts FY26 revenue view to $95M-$100M from $109M-$114M
- OptimizeRx Secures New Credit Facility to Boost Flexibility
- OPRX Earnings this Week: How Will it Perform?